No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
KROS Keros Therapeutics
- 55.610
- -1.990-3.45%
Trading May 10 11:45 ET
2.01BMarket Cap-10798P/E (TTM)
58.425High55.140Low81.22KVolume58.060Open57.600Pre Close4.55MTurnover0.26%Turnover RatioLossP/E (Static)36.08MShares73.00052wk High4.42P/B1.72BFloat Cap27.02052wk Low--Dividend TTM30.94MShs Float88.800Historical High--Div YieldTTM5.70%Amplitude19.100Historical Low56.061Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), Keros Therapeutics (KROS)
HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Keros Therapeutics (NASDAQ:KROS) with a Buy and maintains $100 price target.
Keros Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 71.7% HC Wainwright & Co. → $100 Reiterates Buy → Buy 03/27/2024 80.29% Piper Sandler → $105 Ma
Buy Rating Reaffirmed for Keros Therapeutics as KER-050 Advances Towards Phase 3 for MDS Treatment
Analysts' Top Healthcare Picks: Ascendis Pharma (ASND), Keros Therapeutics (KROS)
Buy Rating Affirmed for Keros Therapeutics: Promising Pipeline and Strong Financial Health
Comments
NHP data from $Regeneron Pharmaceuticals(REGN.US$ 's new slide deck is very relevant for the weight loss space.
Combining pure anti-Myostatin antibodies with Semaglutide was marginally effective in NHPs in preventing muscle loss. I believe that for that reason, $Scholar Rock(SRRK.US$ and probably also $Biohaven(BHVN.US$ are likely to disappoint.
Additionally blocking other ligands like Activin A dramatically improves body composition. That is what $Eli Lilly and Co(LLY.US$ , $Keros Therapeutics(KROS.US$ ...
Combining pure anti-Myostatin antibodies with Semaglutide was marginally effective in NHPs in preventing muscle loss. I believe that for that reason, $Scholar Rock(SRRK.US$ and probably also $Biohaven(BHVN.US$ are likely to disappoint.
Additionally blocking other ligands like Activin A dramatically improves body composition. That is what $Eli Lilly and Co(LLY.US$ , $Keros Therapeutics(KROS.US$ ...
3
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg